title: Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy.
abstract: OBJECTIVE
  To evaluate hepatotoxicity in patients with juvenile idiopathic arthritis (JIA) receiving methotrexate (MTX) therapy with doses of 20-30 mg/m2 of body surface area.
  
  
  METHODS
  We graded the histology of percutaneous liver biopsies from 34 patients with JIA receiving longterm (> 2.4 years) MTX therapy at the Rheumatism Foundation Hospital, Heinola, Finland, using the Roenigk classification scale. Medical records of the patients with JIA were retrospectively analyzed.
  
  
  RESULTS
  Of 10 patients with MTX doses >/= 20 mg/m2, 4 had grade II, 5 had grade I histology, and one specimen with extensive steatosis as the only pathologic finding could not be classified. All 24 patients treated with low dose MTX had grade I histology. No specimen showed fibrosis or cirrhosis. In 2 patients with grade II histology, extensive portal tract inflammation resolved when MTX was discontinued for 6 months.
  
  
  CONCLUSIONS
  Aggressive medical treatment of JIA with MTX at 20-30 mg/m2 with concomitant disease modifying antirheumatic drugs and corticosteroids may contribute to minor liver abnormalities that seem to be reversible.
authors.affiliation: Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland. pekka.lahdenne@hus.fi
authors.forename: Pekka
authors.initials: P
authors.lastname: Lahdenne
authors.forename: Juhani
authors.initials: J
authors.lastname: Rapola
authors.forename: Heikki
authors.initials: H
authors.lastname: Ylijoki
authors.forename: Jarkko
authors.initials: J
authors.lastname: Haapasaari
mesh_terms: D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D008727:Methotrexate